# Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD)

> **NCT05548491** · PHASE2 · COMPLETED · sponsor: **Azura Ophthalmics** · enrollment: 67 (actual)

## Conditions studied

- Contact Lens Discomfort

## Interventions

- **DRUG:** AZR-MD-001 ointment/semi-solid drug

## Key facts

- **NCT ID:** NCT05548491
- **Lead sponsor:** Azura Ophthalmics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-10
- **Primary completion:** 2023-10-13
- **Final completion:** 2023-10-13
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2023-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05548491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05548491, "Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05548491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*